

**Table (1): Comparison of the three studied groups by socio demographic characteristics, family history and chronic illness (N. =85)**

Parameter	Malignant tumor (N=60)	Benign tumor (N=10)	Healthy control (N=15)	P-value
<b>Age</b>				
Mean± S.D.	<b>46.2 ± 18.9</b>	<b>52.8 ± 16.3</b>	<b>34.7 ± 10.9</b>	
Median (Range)	<b>44.5 (15 – 82)</b>	<b>52.5 (25 -75)</b>	<b>36 (20 – 59)</b>	<b>0.024*</b>
<b>Sex</b>				
Males (%)	<b>22 (56.4%)</b>	<b>4 (10.3%)</b>	<b>13 (33.3%)</b>	<b>0.002**</b>
Female s (%)	<b>38 (82.6%)</b>	<b>6 (13.1%)</b>	<b>2 (4.3%)</b>	
<b>Family history</b>				
Negative (%)	<b>46 (83.6%)</b>	<b>9 (16.4%)</b>	--	0.678***
Positive (%)	<b>14 (93.3%)</b>	<b>1 (6.7%)</b>		
<b>Chronic illness</b>				
Yes (%)	<b>14 (66.7%)</b>	<b>7 (33.3%)</b>	--	0.006***
No (%)	<b>46 (93.9%)</b>	<b>3 (6.1%)</b>		

**Table (2): Comparison of Visfatin enzyme levels according to tumor burden (N. = 60)**

Visfatin level is proportionally correlated with tumor burden

Enzyme	High (N=24)	Low (N=36)	P-value
Visfatin (μg/dl)			
Mean± S.D.	<b>15.9 ± 2.7</b>	<b>14.02 ± 2.4</b>	
Median (Range)	<b>16.8 (11.8 – 19.7)</b>	<b>14 (10.9 – 19.1)</b>	<b>0.006*</b>

**Table (3): Comparison of Visfatin enzyme levels according to invasiveness and metastasis (N. = 60)**

Enzyme	Yes (N= 24)	No (N= 36)	P-value
Visfatin (μg/dl)			
Mean± S.D.	<b>17.6 ± 1.3</b>	<b>12.9 ± 1.4</b>	
Median (Range)	<b>17.05 (15.1 – 19.7)</b>	<b>12.8 (10.9 – 15.5)</b>	<b>0.000*</b>

**Table (4): Comparison of Visfatin enzyme levels according to grade (N. =60)Visfatin level is proportionally correlated with tumorgrade**

Enzyme	Grade 1 (N=2)	Grade 2 (N=46)	Grade 3 (N=12)	P-value
Visfatin ( $\mu\text{g/dl}$ )				
Mean $\pm$ S.D.	$14.4 \pm 0.0$	$14.7 \pm 2.7$	$15.4 \pm 3.1$	
Median(Range)	14.4 (14.4 – 14.4)	14.1 (11 -19.7)	16.8 (10.9– 19.1)	0.867

**Table (5): Comparison of Visfatin enzyme levels according to differentiation (N. =60)Visfatin level is proportionally correlated with tumordifferentiation**

Enzyme	Poor differentiation (N=16)	Moderate differentiation (N=38)	Well differentiation (N=6)	P- value
Visfatin ( $\mu\text{g/dl}$ )				
Mean $\pm$ S.D.	$17.8 \pm 1.8$	$13.9 \pm 2.1$	$12.5 \pm 1.5$	
Median(Range)	18.1 (14.1 – 19.7)	14 (10.9 -17.1)	11.7 (11.3– 14.4)	0.000*

**Table (6): Comparison of Visfatin enzyme levels according to stage of cancer (N. =60)Visfatin level is proportionally correlated with stage of cancer**

Enzyme	Stage I (N=10)	Stage I I (N=32)	Stage I II (N=14)	Stage I V (N=4)	P-value
Visfatin ( $\mu\text{g/dl}$ )					
Mean $\pm$ S.D.	$12.4 \pm 1.2$	$13.7 \pm 1.9$	$17.6 \pm 1.05$	$19.4 \pm 0.3$	
Median (Range)	12.5 (11 – 14)	14.1 (10.9 - 17.1)	17 (16.5– 19.7)	19.4 (19.1– 19.7)	0.000*

**Table (7): Comparison of Visfatin enzyme level among the study groups**

Enzyme	Malignant tumor (N=60)	Benign tumor (N=10)	Healthy control (N=15)	P-value	P1	P2	P3
Visfatin ( $\mu\text{g/dl}$ )	$14.8 \pm 2.7$	$5.4 \pm 1.8$	$2.7 \pm 1.2$	0.000*	0.000*	0.001*	0.000*
Mean $\pm$ S.D.	$14.3 (10.9 - 19.7)$	$5.6 (1.4 - 8)$	$2.4 (1 - 5)$				
Median (Range)							

**Table (8): Comparison of Nitric oxide and lipid peroxide and superoxide dismutaseenzyme level among the study groups**

Enzyme	Malignant tumor (N=60)	Benign tumor (N=10)	Healthy control (N=15)	P-value	P1	P2	P3
Nitric oxide(Mmol/L) Mean± S.D. Median (Range)	<b>19.9 ± 2.9</b> <b>20.3 (15 – 25)</b>	<b>8.9 ± 1.5</b> <b>8.4 (7.4-12)</b>	<b>5.1 ± 0.6</b> <b>5 (4.1 – 6)</b>	<b>0.000*</b>	<b>0.000*</b>	<b>0.000*</b>	<b>0.000*</b>
lipid peroxide (µmol/L) Mean± S.D. Median (Range)	<b>6.3 ± 1.1</b> <b>6.2 (4 – 8)</b>	<b>3.6 ± 0.49</b> <b>3.6 (3 -4)</b>	<b>2.3 ± 0.52</b> <b>2 (3 – 4)</b>	<b>0.000*</b>	<b>0.000*</b>	<b>0.001*</b>	<b>0.000*</b>
superoxide dismutase (Unit/L) Mean± S.D. Median (Range)	<b>241.3 ± 56.3</b> <b>230.5</b>	<b>259 ± 26.8</b> <b>245</b>	<b>424.5 ± 24.4</b> <b>425</b>	<b>0.000*</b>	<b>0.000*</b>	<b>0.001*</b>	<b>0.000*</b>